Oncopeptides AB (0RN4) AI Stock Analysis

Oncopeptides AB

(LSE:0RN4)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Rapid revenue growthStrong year-over-year sales growth indicates increasing adoption of Pepaxti across the company’s European commercial footprint. If maintained, the expanding revenue base can improve operating leverage, support investment in commercialization, and move the business closer to covering its fixed cost structure.

Negative Factors

Persistent operating lossesDespite improving from the prior year, the continuing EBIT loss shows that current product revenue does not yet cover the company’s operating base. Until sales scale further or expenses fall materially, profitability remains unproven and management must execute through a prolonged loss-making phase.

Oncopeptides AB (0RN4) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 638.01M
Dividend Yield: ―
Average Volume (3M): 63.66K
Price to Earnings (P/E): -2.1
Beta (1Y): -0.18
Revenue Growth: 87.23%
EPS Growth: 35.27%
Country: UK
Employees: 69
Sector: General
Sector Strength: 55
Industry: Biotechnology

Oncopeptides AB Business Overview & Revenue Model

Company Description

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate...

Oncopeptides AB Earnings Call Summary

Earnings Call Date:Aug 26, 2026(Q2-2026)|% Change Since:2.34%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call was predominantly positive, supported by 62% quarterly revenue growth, 74% first-half growth, a 98% gross margin, improved EBIT loss, strengthened liquidity, European commercial progress, the EMA label-expansion submission, CEE partnership expansion, and clinical advancement in glioblastoma. These positives were moderated by the continuing operating loss, Spain's access and competitive challenges, no Q2 contribution from Greece, delays in Japan, the lack of current U.S. focus, and the still-broad timing for cash flow positivity.

Positive Updates

Strong Revenue Growth

Net sales reached SEK 31.1 million in Q2 2026, representing a 62% increase compared with Q2 2025. First-half net sales reached SEK 56.5 million, up 74% year-over-year.

Negative Updates

Operating Loss Remains Significant

Despite improvement from the prior year, the company reported a first-half EBIT loss of SEK 86.2 million. First-half operating expenses totaled SEK 146.9 million, and quarterly operating expenses were SEK 81.1 million.

Company Guidance

Oncopeptides expects positive cash flow “during 2027,” with sales covering operating expenses, and expects full-year operating expenses “to be in the vicinity of what we had for 2025, i.e., around about SEK 300 million”; Q3 operating expenses are expected to be “slightly lower than Q2.” Following the Type II variation submission between May and July, the company expects the CHMP opinion “sometimes between September to November,” with an EC decision “+30 to 60 days after a potential positive opinion.” For the Salus partnership, “first sales should come sometime in 2027,” while sales in Slovenia can start once a price negotiation is concluded.

Oncopeptides AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0RN4 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SPRINT	79Outperform	SEK 379.86M	5.00	94.09%	―	135.48%	―
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:ATORX	38Underperform	SEK 35.32M	-0.01	-439.98%	―	-99.33%	64.90%

* General Sector Average

Performance Comparison

GB:0RN4 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0RN4	Oncopeptides AB	1.75	-3.87	-68.86%
SE:ATORX	Alligator Bioscience AB	0.01	-0.38	-97.42%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%
SE:SPRINT	Sprint Bioscience AB	3.60	2.88	398.61%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Oncopeptides AB AI Stock Analysis